xCT Inhibition Increases Sensitivity to Vorinostat in a ROS-Dependent Manner
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
xCT Inhibition Increases Sensitivity to Vorinostat in a ROS-Dependent Manner
Authors
Keywords
-
Journal
Cancers
Volume 12, Issue 4, Pages 827
Publisher
MDPI AG
Online
2020-04-01
DOI
10.3390/cancers12040827
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Chaperone-mediated autophagy is involved in the execution of ferroptosis
- (2019) Zheming Wu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Next-generation characterization of the Cancer Cell Line Encyclopedia
- (2019) Mahmoud Ghandi et al. NATURE
- A GPX4-dependent cancer cell state underlies the clear-cell morphology and confers sensitivity to ferroptosis
- (2019) Yilong Zou et al. Nature Communications
- Metabolic Regulation of Redox Balance in Cancer
- (2019) Vinee Purohit et al. Cancers
- ROS Generation and Antioxidant Defense Systems in Normal and Malignant Cells
- (2019) Anastasiya V. Snezhkina et al. Oxidative Medicine and Cellular Longevity
- Insight into the mechanism of ferroptosis inhibition by ferrostatin-1
- (2019) Giovanni Miotto et al. Redox Biology
- Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition
- (2017) Matthew J. Hangauer et al. NATURE
- On the Mechanism of Cytoprotection by Ferrostatin-1 and Liproxstatin-1 and the Role of Lipid Peroxidation in Ferroptotic Cell Death
- (2017) Omkar Zilka et al. ACS Central Science
- ΔNp63/DGCR8-Dependent MicroRNAs Mediate Therapeutic Efficacy of HDAC Inhibitors in Cancer
- (2016) Marco Napoli et al. CANCER CELL
- CD44 variant-dependent redox status regulation in liver fluke-associated cholangiocarcinoma: A target for cholangiocarcinoma treatment
- (2016) Malinee Thanee et al. CANCER SCIENCE
- Ferroptosis: process and function
- (2016) Y Xie et al. CELL DEATH AND DIFFERENTIATION
- Dose-escalation study for the targeting of CD44v+ cancer stem cells by sulfasalazine in patients with advanced gastric cancer (EPOC1205)
- (2016) Kohei Shitara et al. Gastric Cancer
- Global survey of cell death mechanisms reveals metabolic regulation of ferroptosis
- (2016) Kenichi Shimada et al. Nature Chemical Biology
- Ferroptosis: Death by Lipid Peroxidation
- (2016) Wan Seok Yang et al. TRENDS IN CELL BIOLOGY
- Glutathione and Thioredoxin Antioxidant Pathways Synergize to Drive Cancer Initiation and Progression
- (2015) Isaac S. Harris et al. CANCER CELL
- Histone deacetylase inhibitors in cancer therapy. A review
- (2013) Jan Hrabeta et al. BIOMEDICAL PAPERS-OLOMOUC
- Glutamine Sensitivity Analysis Identifies the xCT Antiporter as a Common Triple-Negative Breast Tumor Therapeutic Target
- (2013) Luika A. Timmerman et al. CANCER CELL
- xCT Inhibition Depletes CD44v-Expressing Tumor Cells That Are Resistant to EGFR-Targeted Therapy in Head and Neck Squamous Cell Carcinoma
- (2013) M. Yoshikawa et al. CANCER RESEARCH
- A regulatory circuit that involves HR23B and HDAC6 governs the biological response to HDAC inhibitors
- (2013) M New et al. CELL DEATH AND DIFFERENTIATION
- Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death
- (2012) Scott J. Dixon et al. CELL
- Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed
- (2012) Berkley E Gryder et al. Future Medicinal Chemistry
- Post-translational modifications of Hsp90 and their contributions to chaperone regulation
- (2011) Mehdi Mollapour et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- CD44 Variant Regulates Redox Status in Cancer Cells by Stabilizing the xCT Subunit of System xc− and Thereby Promotes Tumor Growth
- (2011) Takatsugu Ishimoto et al. CANCER CELL
- Disruption of xCT inhibits cell growth via the ROS/autophagy pathway in hepatocellular carcinoma
- (2011) Weijie Guo et al. CANCER LETTERS
- Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound -phenylethyl isothiocyanate
- (2010) Y. Hu et al. BLOOD
- HDACs and HDAC inhibitors in colon cancer
- (2010) John M. Mariadason Epigenetics
- Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy
- (2010) Julia M. Wagner et al. Clinical Epigenetics
- Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862)
- (2009) Deborah Bradley et al. CANCER
- Genome-wide Loss-of-Function Screen Reveals an Important Role for the Proteasome in HDAC Inhibitor-Induced Apoptosis
- (2009) Susan Fotheringham et al. CANCER CELL
- Histone deacetylase inhibitors: Potential in cancer therapy
- (2009) P.A. Marks et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Effective elimination of fludarabine-resistant CLL cells by PEITC through a redox-mediated mechanism
- (2008) D. Trachootham et al. BLOOD
- The x c − cystine/glutamate antiporter as a potential therapeutic target for small-cell lung cancer: use of sulfasalazine
- (2008) Jun Guan et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Histone deacetylase inhibitors: Mechanisms of cell death and promise in combination cancer therapy
- (2008) Jennifer S. Carew et al. CANCER LETTERS
- Constitutive Activation of Signal Transducers and Activators of Transcription Predicts Vorinostat Resistance in Cutaneous T-Cell Lymphoma
- (2008) V. R. Fantin et al. CANCER RESEARCH
- A Phase II Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) in Metastatic Breast Cancer: A California Cancer Consortium Study
- (2008) T. H. Luu et al. CLINICAL CANCER RESEARCH
- Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer
- (2008) Johan Vansteenkiste et al. INVESTIGATIONAL NEW DRUGS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now